Inclusion Criteria:

          -  Histologically confirmed pancreatic ductal adenocarcinoma

          -  Borderline resectable or locally advanced unresectable pancreas cancer as defined by
             the National Comprehensive Cancer Network (NCCN) and determined by a pancreatic
             surgeon prior to therapy. This can be confirmed by the surgeon?s documentation in the
             electronic medical record, by a treatment planning conference note, or by the
             signature of a pancreatic surgeon

          -  Patient has received gemcitabine-based multi-agent chemotherapy regimen or
             fluorouracil, irinotecan, leucovorin, and oxaliplatin (FOLFIRINOX) chemotherapy for
             1-6 months. Enrollment has to occur within 3 months of the day 1 of the last cycle
             given of chemotherapy. Patients who have primary tumor or regional lymph node
             progression on chemotherapy or prior to enrollment are eligible if no distant
             metastases are identified on the screening imaging assessment

          -  Measurable disease as determined by Response Evaluation Criteria in Solid Tumors
             (RECIST) version (v)1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1

          -  Absolute neutrophil count (ANC) >= 1500/uL

          -  Platelets >= 100k/uL

          -  Total Bilirubin =< 2.0 mg/dL

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2.5 x institutional upper limit of normal (ULN)

          -  Serum creatinine < 1.25 md/dL

          -  Serum potassium < 5.0 mmol/L

          -  Negative serum or urine pregnancy test at screening for women of childbearing
             potential

          -  Highly effective contraception for both male and female subjects throughout the study
             and for at least 12 months after last study treatment administration if the risk of
             conception exists

          -  Recovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events
             (CTCAE) v5.0 from toxicities related to any prior treatments, unless AEs are
             clinically nonsignificant and/or stable on supportive therapy

          -  Able to provide informed consent and willing to sign an approved consent form that
             conforms to federal and institutional guidelines

        Exclusion Criteria:

          -  Patients with a prior or concurrent malignancy whose natural history or treatment has
             the potential to interfere with the safety or efficacy assessment of the
             investigational regimen of this trial

          -  Distant metastases. Regional lymphatic disease is acceptable

          -  Prior radiation therapy or definitive resection for pancreatic cancer

          -  Uncontrolled gastric or duodenal ulcer disease within 28 days of registration

          -  Chronic cough, defined 30% of days over 3 months with active symptoms at enrollment or
             over 12 months with last active symptoms occurring 6 months prior to enrollment

          -  Symptomatic hypotension (blood pressure < 90 systolic or < 60 diastolic at screening
             vital sign assessment) that has the potential to interfere with the patient's safety
             or ability to complete protocol treatment, at the discretion of the treating
             investigator

          -  Patients taking > 50mg losartan QD who, at the discretion of the treating
             investigator, cannot be reduced to the protocol defined regimen.

          -  Patients taking an angiotensin II receptor blocker or an angiotensin-converting enzyme
             inhibitor who, at the discretion of the treating investigator, cannot be safely
             discontinued prior to Day 1 dosing.

          -  Patients taking direct renin-angiotensin system inhibitors including aliskiren
             (Rasilez).

          -  Prior allergy to an angiotensin II receptor blocker

          -  Concurrent use of direct renin inhibitor including aliskiren (Rasilez)

          -  Patients with known history of:

               -  Heart failure. Patients with heart failure, should have a clinical risk
                  assessment of cardiac function using the New York Heart Association Functional
                  Classification. To be eligible for this trial, patients should be class 2B or
                  better.

               -  Patients with a prior history of treatment with cardiotoxic agents should be
                  evaluated for heart failure prior to enrollment at the discretion of the treating
                  investigator.

               -  Solitary kidney, renal artery stenosis, or chronic renal failure

          -  Human immunodeficiency virus (HIV)-infected patients who are not on effective
             anti-retroviral therapy or have a detectable viral load within 6 months of trial entry

          -  Patients with known evidence of chronic hepatitis B virus (HBV) infection and a
             detectable HBV viral load

          -  Patients with a history of hepatitis C virus (HCV) infection who have not been treated
             and cured. For patients with HCV infection who are currently on treatment, they are
             eligible if they have an undetectable HCV viral load

          -  Subject is currently enrolled on another investigational treatment study for pancreas
             cancer